APA (7th ed.) Citation

Gion, M., Blancas, I., Cortez-Castedo, P., Cortés-Salgado, A., Marmé, F., Blanch, S., . . . Llombart-Cussac, A. (2025). Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: The ATRACTIB phase 2 trial. Nature medicine, 31(8), . https://doi.org/10.1038/s41591-025-03734-3

Chicago Style (17th ed.) Citation

Gion, María, et al. "Atezolizumab Plus Paclitaxel and Bevacizumab as First-line Treatment of Advanced Triple-negative Breast Cancer: The ATRACTIB Phase 2 Trial." Nature Medicine 31, no. 8 (2025). https://doi.org/10.1038/s41591-025-03734-3.

MLA (9th ed.) Citation

Gion, María, et al. "Atezolizumab Plus Paclitaxel and Bevacizumab as First-line Treatment of Advanced Triple-negative Breast Cancer: The ATRACTIB Phase 2 Trial." Nature Medicine, vol. 31, no. 8, 2025, https://doi.org/10.1038/s41591-025-03734-3.